Please login to the form below

Not currently logged in
Email:
Password:

John Brown joins board of BioCity Nottingham

Appointment follows expansion of BioCity's operations to Scotland

Dr John Brown, current chair of CXR Biosciences, has been appointed to the board of directors at BioCity Nottingham – one of Europe's largest life sciences research parks.

Dr Brown is also currently non-executive director of Vectura Group, chair of the Roslin Foundation in Scotland and co-chair of the Life Sciences Industry Advisory Board for the Scottish Government.

Other public sector work includes serving as non-executive director of the UK's Technology Strategy Board, a national agency to support innovation in business.

His appointment comes shortly after BioCity Nottingham announced plans to extend its operations, with the launch of BioCity Scotland in January, 2012, using a research facility formerly owned by Merck Sharp & Dohme.

Commenting on his appointment, Dr Brown said: “I'm delighted to be working with the BioCity team. Emulating the successful BioCity model at BioCity Scotland is just the first step for a company with exceptional growth potential.''

Previous positions held by Dr Brown in an extensive career in the life sciences industry include chair of both BTG and Axis-Shield, as well as spending five years at Glaxo Group Research.

He was also chief executive of UK-based vaccines biotech Acambis from 1997 until 2003.

Dr Louis Nisbet, chair of BioCity said: “Few individuals have the depth and breadth of experience that [Dr Brown] will bring to BioCity and to the companies we support.”

14th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics